Chlordiazepoxide withdrawal in the neonate

Athinarayanan, Pakshi; Pierog, Sophie; Nigam, Sarvesh; Glass, Leonard

doi:10.1016/s0002-9378(16)33306-3

Cited by 69 publications

(9 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When evaluating the findings it has to be borne in mind that psychoactive drugs protect the unborn child from possible damage through metabolie sequelae of psychiatrie illness such as starving in severe depression, self-neglect and vagrancy in schizophrenia, or excessive movement and alcohol consumption in mania. Drugs ingested by the mother before delivery can have toxie effects in the newborn which may last for some days because of the slow metabolism of the immature organism, and withdrawal symptoms may develop with some delay (Athinarayanan et al, 1976;Cleary, 1977;Gilberg, 1977;Hammond and Toseland, 1970;Hili et al, 1966;Morselli et al, 1973;Musa, 1979;O'Connor et al, 1981;0stergaard, 1982;Speight, 1977;Tanner et al, 1969). 8.…”

Section: Description and Evaluation Of Methods Used In The Researchmentioning

confidence: 99%

Pharmacotherapy of Psychiatric Disorder in Pregnancy and during Breastfeeding: A Review

Thiels¹

1987

Pharmacopsychiatry

View full text Add to dashboard Cite

The literature in most European languages was consulted for guidelines regarding the drug treatment of psychiatrically disturbed pregnant or lactating women. The available information allows only a few conclusions. Lithium exposure during the first trimester seems to increase the risk of congenital heart disease, especially Ebstein's anomaly. As there is still insufficient evidence to prove the safeness of other psychoactive drugs for the fetus, caution seems warranted here too. A causal link between pharmacotherapy of the mother-to-be and malformation of the baby is difficult to prove. But toxic and withdrawal symptoms in infants born to women treated regularly until shortly before confinement are well documented for most psychoactive drugs.

show abstract

Section: Description and Evaluation Of Methods Used In The Researchmentioning

confidence: 99%

Pharmacotherapy of Psychiatric Disorder in Pregnancy and during Breastfeeding: A Review

Thiels¹

1987

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

“…In the majority of cases, however, the drugs have been taken for much longer, usually a few years [35,42,43,44,45,46,47,48,49,50]. Finally, two reports have described apparent withdrawal symptoms in neonates following maternal exposure to benzodiazepines [51,52].…”

Section: Clinical Dependencementioning

confidence: 99%

Benzodiazepine Dependence

Pétursson

Lader

1981

British Journal of Addiction

160

View full text Add to dashboard Cite

Summary Benzodiazepines, the most widely used of all drugs, are powerful anxiolytics, anticonvulsants and muscle relaxants. Dependence is difficult to induce in animals but has been induced by high doses in man. Case reports of benzodiazepine dependence are rare compared with the usage of these drugs, but do not provide a proper epidemiological framework for the estimation of risk. Patients taking these drugs for four months or more may develop a physical withdrawal syndrome, characterized by anxiety, dysphoria, malaise, depersonalization, and by perceptual changes such as hyperacusis and unsteadiness. In our experience drawn from over 20 patients, withdrawal from therapeutic doses of a benzodiazepine may be attended by a fully‐developed physical withdrawal syndrome.

show abstract

“…Among neonates exposed to opioids in utero, withdrawal signs will develop in 55% to 94%. [6][7][8][9] Neonatal withdrawal signs have also been described in infants exposed antenatally to benzodiazepines, 10,11 barbiturates, 12,13 and alcohol.…”

mentioning

confidence: 99%

Neonatal Drug Withdrawal

Hudak¹,

Tan²,

Frattarelli³

et al. 2012

Pediatrics

742

608

View full text Add to dashboard Cite

Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.

show abstract

Chlordiazepoxide withdrawal in the neonate

Cited by 69 publications

References 1 publication

Pharmacotherapy of Psychiatric Disorder in Pregnancy and during Breastfeeding: A Review

Pharmacotherapy of Psychiatric Disorder in Pregnancy and during Breastfeeding: A Review

Benzodiazepine Dependence

Neonatal Drug Withdrawal

Contact Info

Product

Resources

About